Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.

Advertisement

Related Content

Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster
Big Pharma’s Gamble On HDL Hypothesis
Merck Makes Hepatitis C A Priority
Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs
Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
Pfizer's Global R&D Network: Rapid Integration Means Doing More With Less
Merck Taking Aggressive Approach To Cardiovascular Development
Merck's Cordaptive: Just Another Cholesterol Combo, or More?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS004888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel